Back

Risk of stroke in patients with type 2 diabetes receiving semaglutide or a dipeptidyl peptidase-4 inhibitor: a real-world US claims database analysis

26 August 2022 (08:00 - 19:30)
Organised by:
Congress Presentation Part of: Medical management and risk factors Pharmacotherapy ESC Professional Premium Access ESC Congress 2022

About the speaker

Photo
Doctor Marc Evans

Cardiff (United Kingdom of Great Britain & Northern Ireland)

4 More presentations in this session

Presentation thumbnail
Predictive value of neutrophil-to-lymphocyte ratio for atrial fibrillation and stroke in type 2 diabetes mellitus: a population-based cohort study
Mr T. Lee (Hong Kong, HK)
Abstract Slides
Presentation thumbnail
Celiprolol to prevent arterial events in patients with vascular Ehlers-Danlos and neither symptomatic nor silent arterial event. A retrospective cohort study from the French national reference center
Professor T. Mirault (Paris, FR)
Abstract Slides
Presentation thumbnail
Inequalities in accessing quality healthcare, does insurance play a role? retrospective analysis of aortic emergencies from national inpatient sample 2019.
Doctor S. Vohra (New York City, US)
Abstract Slides
Presentation thumbnail
Four-month treatment with long-acting glucagon-like peptide-1 receptor agonists (GLP-1) or sodium-glucose co-trasporter-2 inhibitors (SGLT-2i) improves vascular function in type 2 diabetes mellitus
Doctor I. Ikonomidis (Athens, GR)
Abstract Slides

Access the full session

Session thumbnail
Medical management and risk factors

The Event

Event poster

ESC Congress 2022

26 August - 29 August 2022

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources